The Next Stage of Buprenorphine Care for Opioid Use Disorder
The DOI matches its Crossref record; 58 of the 60 references it cites were found in a registry or an index.
Abstract
Buprenorphine has been used internationally for the treatment of opioid use disorder (OUD) since the 1990s and has been available in the United States for more than a decade. Initial practice recommendations were intentionally conservative, were based on expert opinion, and were influenced by methadone regulations. Since 2003, the American crisis of OUD has dramatically worsened, and much related empirical research has been undertaken. The findings in several important areas conflict with initial clinical practice that is still prevalent. This article reviews research findings in the following 7 areas: location of buprenorphine induction, combining buprenorphine with a benzodiazepine, relapse during buprenorphine treatment, requirements for counseling, uses of drug testing, use of other substances during buprenorphine treatment, and duration of buprenorphine treatment. For each area, evidence for needed updates and modifications in practice is provided. These modifications will facilitate more successful, evidence-based treatment and care for patients with OUD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, while our GBOT model includes psychoeducation components with varying degrees of rigor, psychotherapeutic counseling is not necessary for successful outcomes in B/N treatment.21”
From Implementing Group Visits for Opioid Use Disorder: A Case Series (2020) · cites this paper as [21]
Citations
Cites
Extensional versus intuitive reasoning: The conjunction fallacy in probability judgment.
Tversky, A., & Kahneman, D. (1983) · Psychological Review · doi:10.1037/0033-295x.90.4.293 · Cited by 3,991
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076 · cited 1×
“Buprenorphine, the most commonly used evidencebased treatment of OUD (73, 74) in the United States, is associated with reduced mortality (75, 76).”
BackgroundMedication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,015
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 910
Tolerating Uncertainty — The Next Medical Revolution?
Simpkin, A. L., & Schwartzstein, R. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1606402 · Cited by 521
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466 · cited 1×
“Early cessation of buprenorphine treatment can have catastrophic effects, including death (21, 64).”
BackgroundDrugs Most Frequently Involved in Drug Overdose Deaths: United States, 2011-2016.
Hedegaard, H. B., Bastian, B. A., Trinidad, J. P., Spencer, M. R. T., & Warner, M. (2018) · PubMed · Cited by 394
Dugosh, K., Abraham, A., Seymour, B., McLoyd, K., Chalk, M., & Festinger, D. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000193 · Cited by 333 · cited 1×
“A systematic review of psychosocial counseling provided with MAT found that “support for the efficacy of delivering concurrent psychosocial interventions was less robust for buprenorphine” (45).”
Cornish, R., Macleod, J., Strang, J., Vickerman, P., & Hickman, M. (2010) · BMJ · doi:10.1136/bmj.c5475 · Cited by 307 · cited 1×
“A 2010 analysis found no reduction in mortality until 20 weeks of treatment; opioid substitution treatment for 12 months or longer was needed to achieve a chance greater than 85% of reducing overall mortality (66).”
Background
Research works printed but not linked: 5
- Sansone RA, 2015, Innov Clin Neurosci, 12, 32
- Warner M, 2016, Natl Vital Stat Rep, 65, 1
- Knopf A, 2017, Alcoholism & Drug Abuse Weekly, 29, 3
- Gabrielson R, 2016, The New York Times, MM34
- Jones CM, 2014, MMWR Morb Mortal Wkly Rep, 63, 881
Cited by
Items 101–135 of 135
Seliski, N., Madsen, T. E., Eley, S., Colosimo, J., Engar, T., Gordon, A. J., Barnett, C., Humiston, G. E., Morsillo, T., Stolebarger, L., et al. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00496-0 · Cited by 2
Masyukova, M., Hayes, B. T., López‐Castro, T., & Fox, A. D. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00540-7 · Cited by 2
Induction of Medication for Opioid Use Disorder in Primary Care
Hall, T. L., Fernald, D. H., Jiang, V., Curcija, K., LeMaster, J. W., Westfall, J. M., Nease, D. E., & ZITTLEMAN, L. K. (2025) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2024.240317r1 · Cited by 2
Public interest in medication-assisted treatment for opioid used disorder in the United States
Niforatos, J. D., Zheutlin, A. R., Pescatore, R. M., & Raja, A. S. (2019) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2019.04.021 · Cited by 2
Balancing Benefits and Harms on the Frontier of Buprenorphine Initiation
Strayer, R. J., Herring, A. A., & Nelson, L. S. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.04.024 · Cited by 2
Laboratory monitoring for patients on buprenorphine: 10 questions
Hale, C. V. (2022) · Current Psychiatry · doi:10.12788/cp.0282 · Cited by 1
Palliative Care for Geriatric Psychiatric Patients with Life-Limiting Illness
Leung, M. W., Santo, E. C., Kaplan, L. E., & Bourgeois, J. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-47802-4_31 · Cited by 1
State‐level racial and ethnic disparities in buprenorphine treatment duration in the United States
Dong, H., Stringfellow, E. J., & Jalali, M. S. (2024) · American Journal on Addictions · doi:10.1111/ajad.13638 · Cited by 1
Henderson, C., Walker, S., Lloyd, Z., Gibbs, D., Romero, L., & Stoove, M. A. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-106054 · Cited by 1
Mannelli, P., & Wu, L.-T. T. (2019) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_3_19 · Cited by 1
Sublingual Buprenorphine Initiation: The Traditional Method #441
Jones, K. F., Ho, J. J., Sager, Z. S., Broglio, K., & Childers, J. W. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0135 · Cited by 1
Prevalence of Polydrug Use in Patients Undergoing Methadone Assisted Therapy in Nairobi County
Kiiru, R. N., Waithima, C. W., & Mwangi, P. K. (2022) · Kabarak journal of research and innovation. · doi:10.58216/kjri.v12i1.68 · Cited by 1
Stringfellow, E. J. (2019) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/4tcp-6m79 · Cited by 1
Oliva, E. M. (2020) · Addiction · doi:10.1111/add.14990 · Cited by 1
The Next Stage of Buprenorphine Care for Opioid Use Disorder
Malinoff, H. L. (2019) · Annals of Internal Medicine · doi:10.7326/l19-0141
The Next Stage of Buprenorphine Care for Opioid Use Disorder
Duncan, M. H., Ratzliff, A., Powers, D. M., Banta‐Green, C. J., & Saxon, A. J. (2019) · Annals of Internal Medicine · doi:10.7326/l19-0144
The Next Stage of Buprenorphine Care for Opioid Use Disorder
Scolnick, B. (2019) · Annals of Internal Medicine · doi:10.7326/l19-0142
The Next Stage of Buprenorphine Care for Opioid Use Disorder
Sherrick, R. C. (2019) · Annals of Internal Medicine · doi:10.7326/l19-0143
Buprenorphine for Long-Term Chronic Pain Management: Still Looking for the Evidence
Chou, R., Ballantyne, J. C., & Lembke, A. (2020) · Annals of Internal Medicine · doi:10.7326/l19-0684
Dai, Z. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7640
Removing the stigma of medication for opioid use disorder
Franko, T. S. (2020) · Pharmacy Today · doi:10.1016/j.ptdy.2020.10.028
EVALUATION OF MEDICATIONS FOR OPIOID USE DISORDER ON OVERDOSE AND HEALTHCARE UTILIZATION IN THE US
Sun, T. (2021) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/sun-tianyu-2021
Guidance for emergency medicine pharmacists to improve care for people with opioid use disorder
Kelsch, J., Bailey, A. M., Baum, R. A., Metts, E. L., & Weant, K. A. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1567
(2019) · Elsevier eBooks · doi:10.1016/b978-0-323-68017-2.16001-6
Lepley, J. (2023) · Journal of Addictive Diseases · doi:10.1080/10550887.2023.2212544
Ethical and Legal Considerations
Martinez, N. G., & Fingerhood, M. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197796207.003.0017
Thakarar, K., Kohut, M., Hutchinson, R., Bell, R., Loeb, H. E., Burris, D., & Fairfield, K. M. (2022) · Figshare · doi:10.6084/m9.figshare.20363548
Thakarar, K., Kohut, M. R., Hutchinson, R., Bell, R., Loeb, H. E., Burris, D., & Fairfield, K. M. (2022) · Figshare · doi:10.6084/m9.figshare.20363551
Sobel, H. G., Warrington, J. S., Francis-Fath, S., Crocker, A. M., & Berger, C. A. (2021) · Figshare · doi:10.6084/m9.figshare.16713981
Simpson, M., Ritger, C., Hoppe, J. A., Holland, W. C., Morris, M. A., Nath, B., Melnick, E. R., & Tietbohl, C. K. (2024) · Figshare · doi:10.6084/m9.figshare.26583897
Addiction: Sex and gender evidence in alcohol, nicotine, and opioid use disorders
Marcus, M. M., Terplan, M., & Martin, C. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00009-4
Muñoz‐Violant, S. (n.d.) · Summit (Simon Fraser University)
Essentials for Treating Behavioral Health in Primary Care
Williamson, M. L. C., & Terry, D. L. (2026) · Springer eBooks · doi:10.1007/978-3-032-09558-9
Treatment of Substance Use Disorders in Primary Care
Martin, M. P., Marshall, C., Nanda, M. A., & Sokol, R. G. (2026) · Springer eBooks · doi:10.1007/978-3-032-09558-9_10
Campbell, B., Riback, L. R., Portillo, J. G., Maricic, S., & Fox, A. D. (2026) · Addiction Science & Clinical Practice · doi:10.1186/s13722-026-00665-3
Metadata
- Authors
- Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- University of Massachusetts Amherst (US)
- CleanSlate Research and Education Foundation, Florence, Massachusetts (A.W.)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2018-11-06
- Volume
- 169
- Issue
- 9
- Pages
- 628-635
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2898142040
- Cited by
- 130
- References
- 60
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 11 · 2023: 10 · 2022: 26 · 2021: 29 · 2020: 17 · 2019: 25 · 2018: 1
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine, opioid use disorder, opioid substitution therapy, relapse, drug testing, polydrug use, treatment duration, evidence-based practice
- MeSH terms
- Benzodiazepines, Buprenorphine, Central Nervous System Agents, Counseling, Drug Therapy, Combination, Humans, Narcotic Antagonists, Opioid-Related Disorders, Recurrence, Substance Abuse Detection, Practice Guidelines as Topic, Patient-Centered Care, Evidence-Based Medicine, Opiate Substitution Treatment, Induction Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.